GS vs PFE: Which Is the Better Buy?
Side-by-side comparison of The Goldman Sachs Group, Inc. and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-07-14.
The Goldman Sachs Group, Inc. · Financial Services
$1,045.91
-45.0% upside to fair value
Grade D
VS
Pfizer Inc. · Healthcare
$25.22
+2.8% upside to fair value
Grade B
QuantHub Verdict
PFE has more upside to fair value
(+2.8%).
PFE trades at a lower forward P/E
(19.2x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
GS |
PFE |
| Current Price |
$1,045.91 |
$25.22 |
| Fair Value Estimate |
$575.25 |
$25.92 |
| Upside to Fair Value |
-45.0%
|
+2.8%
|
| Market Cap |
$308.6B |
$143.7B |
| Forward P/E |
23.6x
|
19.2x
|
| EV / EBITDA |
15.9x
|
12.3x
|
| Price / Sales |
3.1x
|
2.3x
|
| Price / FCF |
-7.4x
|
15.2x
|
| Revenue Growth YoY |
-35.0%
|
+5.4%
|
| Gross Margin |
47.4%
|
69.3%
|
| Operating Margin |
17.8%
|
23.4%
|
| Return on Equity |
15.3%
|
8.4%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
—
|
6.6%
|
| Analyst Consensus |
Hold
|
Hold
|
Investment Thesis
The Goldman Sachs Group, Inc. operates as a leading global financial services firm specializing in investment banking, securities, investment management, and consumer banking. Despite its strong brand and competitive position in financial capital markets, the company currently faces significant headwinds as evidenced by a 35% decline in revenue and a 100% drop in earnings in the most recent quart…
Pfizer Inc. is a leading global biopharmaceutical company with a diversified portfolio dominated by its Biopharma prescription segment, which accounts for over 90% of revenue. The company benefits from a substantial scale, a broad product portfolio including top-selling drugs like Eliquis, Prevnar, and Paxlovid, and a strong manufacturing footprint. However, Pfizer faces challenges from declining…
Accumulation Zones
| Metric |
GS |
PFE |
| Zone Low |
$431.44 |
$19.44 |
| Zone High |
$488.96 |
$22.03 |
| In Buy Zone? |
No
|
No
|